^
BIOMARKER:

KRAS exon 3 mutation

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
10/05/2021
Initiation :
11/23/2020
Primary completion :
10/30/2022
Completion :
12/08/2022
KRAS
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS exon 2 mutation • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
irinotecan • BI 1701963
Phase 2
Criterium, Inc.
Recruiting
Last update posted :
07/05/2021
Initiation :
12/02/2019
Primary completion :
09/01/2022
Completion :
12/01/2022
KRAS
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
Phase 3
GERCOR - Multidisciplinary Oncology Cooperative...
Recruiting
Last update posted :
06/16/2021
Initiation :
10/30/2013
Primary completion :
06/01/2021
Completion :
06/01/2021
KRAS • NRAS
|
NRAS mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
Phase 2
AIO-Studien-gGmbH
Active, not recruiting
Last update posted :
04/27/2021
Initiation :
04/01/2011
Primary completion :
06/01/2017
Completion :
01/01/2022
EGFR • KRAS • NRAS • PTEN • ERCC1 • MTHFR
|
EGFR mutation • PIK3CA mutation • KRAS exon 2 mutation • EGFR exon 18 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
Grupo Espanol Multidisciplinario del Cancer Dig...
Active, not recruiting
Last update posted :
02/03/2021
Initiation :
05/30/2017
Primary completion :
10/31/2020
Completion :
10/31/2022
BRAF • KRAS • NRAS
|
KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium
Phase 1
NYU Langone Health
Completed
Last update posted :
10/12/2020
Initiation :
09/01/2016
Primary completion :
03/12/2020
Completion :
03/12/2020
BRAF • KRAS • NRAS
|
BRAF mutation • KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation
|
adavosertib (AZD1775) • irinotecan
Phase 4
Dr. Reddy's Laboratories Limited
Recruiting
Last update posted :
12/16/2019
Initiation :
07/28/2015
Primary completion :
06/30/2021
Completion :
01/31/2022
KRAS • NRAS
|
NRAS mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Vectibix (panitumumab)
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
10/29/2019
Initiation :
01/01/2018
Primary completion :
12/30/2020
Completion :
12/30/2022
KRAS • NRAS
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 1
AstraZeneca
Completed
Last update posted :
10/04/2019
Initiation :
05/15/2017
Primary completion :
01/08/2019
Completion :
01/08/2019
KRAS
|
KRAS mutation • KRAS G12 • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
AZD4785
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
09/20/2016
Initiation :
01/01/2015
Primary completion :
01/01/2018
Completion :
01/01/2020
KRAS • NRAS
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
AIO-Studien-gGmbH
Completed
Last update posted :
04/19/2016
Initiation :
05/01/2011
Primary completion :
01/01/2015
Completion :
03/01/2016
KRAS
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Vectibix (panitumumab) • doxycycline • erythromycin
Phase 2
WiSP Wissenschaftlicher Service Pharma GmbH
Active, not recruiting
Last update posted :
01/13/2016
Initiation :
12/01/2010
Primary completion :
01/01/2016
Completion :
07/01/2016
KRAS
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Vectibix (panitumumab)